Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pei-Jean Feng

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
MMWR. Morbidity and Mortality Weekly Report|March 24, 2022
Tuberculosis - United States, 2021Thomas D Filardo, Pei-Jean Feng, Robert H Pratt, et al.
The Lancet. Infectious Diseases|January 29, 2022
Discordant results of tests for tuberculosis reconsidered - Authors' replyChristine S Ho, Pei-Jean Feng, Masahiro Narita, et al.
Microbiology Insights|December 4, 2018
Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and CompletionLauren A Lambert, Dolly Katz, Pei-Jean Feng, et al.
Thorax|July 9, 2018
Evaluating latent tuberculosis infection diagnostics using latent class analysisJason E Stout, Yanjue Wu, Christine S Ho, et al.
Journal of Clinical Microbiology|March 4, 2021
Impact of T-Cell Xtend on T-SPOT.<i>TB</i> Assay in High-Risk Individuals after Delayed Blood Sample ProcessingPei-Jean Feng, Yanjue Wu, Christine S Ho, et al.
Contemporary Clinical Trials|April 2, 2023
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentineNigel A Scott, Claire Sadowski, Andrew Vernon, et al.
Annals of Internal Medicine|November 9, 2017
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized TrialRobert Belknap, David Holland, Pei-Jean Feng, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2021
Incidence and Clinical Characteristics of and Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Pregnant Individuals in the United StatesFatimah S Dawood, Michael Varner, Alan Tita, et al.
Contemporary Clinical Trials|January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trialSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
MMWR. Morbidity and Mortality Weekly Report|March 24, 2022
Tuberculosis - United States, 2021Thomas D Filardo, Pei-Jean Feng, Robert H Pratt, et al.
The Lancet. Infectious Diseases|January 29, 2022
Discordant results of tests for tuberculosis reconsidered - Authors' replyChristine S Ho, Pei-Jean Feng, Masahiro Narita, et al.
Microbiology Insights|December 4, 2018
Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and CompletionLauren A Lambert, Dolly Katz, Pei-Jean Feng, et al.
Thorax|July 9, 2018
Evaluating latent tuberculosis infection diagnostics using latent class analysisJason E Stout, Yanjue Wu, Christine S Ho, et al.
Journal of Clinical Microbiology|March 4, 2021
Impact of T-Cell Xtend on T-SPOT.<i>TB</i> Assay in High-Risk Individuals after Delayed Blood Sample ProcessingPei-Jean Feng, Yanjue Wu, Christine S Ho, et al.
Contemporary Clinical Trials|April 2, 2023
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentineNigel A Scott, Claire Sadowski, Andrew Vernon, et al.
Annals of Internal Medicine|November 9, 2017
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized TrialRobert Belknap, David Holland, Pei-Jean Feng, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2021
Incidence and Clinical Characteristics of and Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Pregnant Individuals in the United StatesFatimah S Dawood, Michael Varner, Alan Tita, et al.
Contemporary Clinical Trials|January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trialSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Pageof 1